Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients

Vandana Singh

March 7, 2025

Benzinga

On Friday, Eli Lilly And Co (NYSE:LLY) released new results from Ebglyss’s (lebrikizumab-lbkz) long-term study, ADjoin.

New data shows Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years.

Ebglyss was approved in the U.S. in September 2024 as a first-line monotherapy biologic treatment option following topical prescription therapies.

Of the patients who responded to treatment at Week 16 and received once-monthly maintenance dosing, 50% achieved complete skin clearance (EASI 100 or IGA 0) at three years.

Also Read: Alzheimer’s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding

Additionally, 87% achieved or maintained almost-clear skin (EASI 90) at three years.

Over 83% of Week 16 responders taking EBGLYSS did not require concomitant therapies such as topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) for the duration of the ADjoin study.

Additional study assessments conducted in patients with skin of color (ADmirable) and patients who were previously treated with Regeneron Pharmaceuticals Inc (NASDAQ:REGN) / Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) (ADapt) showed improvements in itch, skin pain (discomfort and soreness), and itch interference with sleep.

In ADmirable, nearly 60% of patients achieved significant improvement in itch and skin pain at Week 16 (58% and 59%, respectively). Over 30% of patients saw a reduction in sleep loss due to itch at Week 16.
In ADapt, 75% achieved significant improvement in skin pain, and 62% achieved significant improvement in itch at Week 24. 42% of patients saw a reduction in sleep loss due to itch at Week 24.

Price Action: LLY stock is down 0.36% at $909.50 during the premarket session at the last check Friday.

Read Next: